-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Today Sage announced that its GABAA receptor positive modulator SAGE-324 has reached its primary endpoint in a phase II clinical trial of essential tremor.
Drug source analysis
Essential tremor is the most common muscle dysfunction.
It is generally believed that essential tremor and epilepsy are caused by central electrophysiological disorders, and Sage's central steroid series of drugs were originally designed for rare epilepsy.
Both types of drugs have an effect on sleep, and drowsiness and dizziness can be said to be mechanism-related side effects.
SAGE-324 is not the core asset of Sage.